2024-03-21 19:00:19 ET
Summary
- Positive results achieved in phase 2 study using survodutide for the treatment of patients with MASH; Primary endpoint of histological improvement of MASH met with statistical significance.
- The global non-alcoholic steatohepatitis [NASH] market size is expected to grow to $14.53 billion in 2028.
- Survodutide has already achieved positive results in a phase 2 study treating patients with obesity; Phase 3 SYNCRHONIZE program already underway with five studies.
- The global obesity market could reach $77 billion in 2030; Survodutide, ZP6590, Petrelintide and Dapiglutide are drugs that are all being advanced to target the large obesity treatment space.
Zealand Pharma ( ZLDPF ) is an under-the-radar biotech company that has established a well-defined pipeline. It has a drug by the name of survodutide [formerly known as BI456906] that it co-invented with another big pharma by the name of Boehringer Ingelheim . This drug is an important one to watch, because Zealand along with its partner, just reported positive results from a phase 2 study using survodutide, to treat patients with non-alcoholic steatohepatitis [NASH]. Now, it is referred to as MASH or metabolic dysfunction-associated steatohepatitis. How can investors benefit from this release of data, and from taking a look at investing in this particular biotech? Well, that's because the company stated in its press release that it intends to release the full data set from this phase 2 study in the coming months at an upcoming medical conference....
Read the full article on Seeking Alpha
For further details see:
Zealand Pharma: Survodutide Has Potential Beyond Obesity Treatment